An investigational antibody-drug conjugate administered intravenously every 2–3 weeks. It uses a monoclonal antibody to bind an unspecified tumor-associated antigen on malignant solid tumor cells, is internalized, and releases an intracellular cytotoxic payload to kill cancer cells; pharmacokinetics and immunogenicity are evaluated.